Abbonarsi

Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: Are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study - 28/08/11

Doi : 10.1067/mhj.2003.6 
Gad Cotter, MDa, Christopher P. Cannon, MDb, Carolyn H. McCabe, BSb, Yoav Michowitz, MDa, Edo Kaluski, MDa, Andrew Charlesworth, BScc, Olga Milo, MDa, Jane Bentley, BScc, Alex Blatt, MDa, Rikardo Krakover, MDa, Reuven Zimlichman, MDc, Leonardo Reisin, MDe, Alon Marmor, MDf, Basil Lewis, MDg, Zvi Vered, MDa, Avi Caspi, MDh, Eugene Braunwald, MDb

OPUS-TIMI 16 Investigators

From the Cardiology Institutes of aAssaf-Harofeh Medical Center, Zerifin, Israel, bBrigham and Women's Hospital, Boston, Mass, cNottingham Clinical Research Group, Nottingham, United Kingdom, dWolfson Medical Center, Holon, eBarzilai Medical Center, Ashkelon, fRebecca Sieff Government Hospital, Safed, gLady-Davis medical center, Haifa, and hKaplan medical center, Rehoveot, Israel. 

Abstract

Background Cerebrovascular accidents (CVAs), transient ischemic attacks (TIAs), and peripheral arterial disease (PAD) frequently coexist with coronary artery disease (CAD) and were previously reported to adversely affect the prognosis of patients with chronic CAD. Methods We examined the effect of prior CVA/TIA or PAD (extra-cardiac vascular disease [EVD]) on the outcome of 10,281 patients with acute coronary syndromes enrolled in the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis in Myocardial Infarction (OPUS-TIMI) 16 trial of the oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin versus aspirin alone. We evaluated mortality, recurrent cardiac events, and stroke and used multivariate analysis to control for differences in baseline characteristics. Results Patients with EVD were older, had more coronary risk factors, had a history of CAD, and received more intensive medical treatment at baseline. The acute event in these patients was more often unstable angina pectoris and less commonly Q-wave myocardial infarction. With coronary angiography, patients with prior EVD more often had multivessel disease. During the 10 months of follow-up, the presence of EVD was predictive of an increased hazard of death, reinfarction, recurrent ischemia, stroke, and a composite of these events. Despite the increased severity of the CAD and increased risk of events, patients with EVD were treated less frequently with β-blockers and more frequently with calcium blockers. Despite patients with EVD having a 45% higher incidence of hypercholesterolemia, lipid-lowering agents were prescribed in a similar percentage of patients as patients without EVD. Conclusion In patients with acute coronary syndromes, the presence of prior CVA, TIA, or PAD is associated with more extensive CAD and worse outcome. These patients appear to receive less aggressive treatment, which may explain, at least in part, their worse outcome. (Am Heart J 2003;145:622-7.)

Il testo completo di questo articolo è disponibile in PDF.

© 2003  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 145 - N° 4

P. 622-627 - Aprile 2003 Ritorno al numero
Articolo precedente Articolo precedente
  • Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease
  • Franz-Xaver Kleber, Christian Witt, Günter Vogel, Klaus Koppenhagen, Ulrike Schomaker, Curt Werner Flosbach, THE-PRINCE Study Group
| Articolo seguente Articolo seguente
  • Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease: Implications for clinical practice
  • Oscar C. Marroquin, Richard Holubkov, Daniel Edmundowicz, Cheryl Rickens, Gerald Pohost, Steven Buchthal, Carl J. Pepine, George Sopko, Robert C. Sembrat, Carolyn Cidis Meltzer, Steven E. Reis

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.